Pediatrics

The results of a review by Murdoch Children’s Research Institute finds that pediatric patients who are vaccinated get protection from the long-term effects of the disease.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

The condition is not preventable, but there are steps that can be taken to reduce LDL-C levels in children.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses the value of the pharmacist in administering COVID-19 vaccines to adolescents and children.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses how health care professionals should approach discussing issues around vaccine hesitancy with parents.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses his decision to enroll his twin daughters in the Moderna COVID-19 vaccine trial.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, on the future of COVID-19 disease and vaccines for adolescents and children.

Hannah Fish, PharmD, associate director of strategic initiatives at NCPA, discusses the role of the pharmacist in vaccinating children ages 12 and older against COVID-19 following the FDA updating the Pfizer COVID-19 vaccine EUA.

Hannah Fish, PharmD, National Community Pharmacists Association associate director of Strategic Initiatives, discusses the next phase of the COVID-19 vaccination rollout following the FDA expanding the Pfizer-BioNTech COVID-19 vaccine EUA to include children ages 12 and older.

This data could offer additional insights into how the pandemic may be impacting the nation's children, according to the study authors.

The FDA has expanded its approval of short ragweed pollen allergen extract (Ragwitek; ALK) to include treatment for children and adolescents, starting at age 5 years, with short ragweed pollen-induced allergic rhinitis.

Despite significant decreases in 2020, a large number of adolescents less than 18 years of age continue to use e-cigarettes, with considerable adverse health effects, according to a presentation at the 2021 National Association of Pediatric Nurse Practitioners (NAPNAP) conference.

First approved by the FDA in 1989 for 2 rare eye muscle disorders, onabotulinumtoxinA (Botox; Allergan) was the world’s first approved botulinum toxin type A treatment.

Push continues for more access to EpiPens, but it is important to protect health care providers who administer the treatment.

Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.

Clinicians often reserve vigilance with drug-related issues for critically ill patients or older populations, while mistaking the resilience of childhood as a protective barrier.

A table showing recommended immunization schedules for child and adolescent patients.

Pharmacy Times spoke with Suzanne Soliman, PharmD, BCMAS, about how pharmacists can prepare their patients for the back-to-school season amid the COVID-19 pandemic and the upcoming flu season.

Pharmacy Times will continue to bring readers the latest information on COVID-19 developments, in a variety of formats.

Risdiplam is the first at-home, orally administered treatment for spinal muscular atrophy in adults and children aged 2 months and older.

How did switching from name brand to generic cause a child’s death?

Staying up-to-date on immunizations is crucial to prevent outbreaks of vaccine-preventable diseases.

CPP is a rare disease defined as the onset of puberty before age 8 years in girls and before age 9 years in boys.

Efinaconazole was first approved by the FDA in June 2014 for patients 18 and older.

The kinase inhibitor selumetinib was approved for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.